Stephen M. Ansell, MD, PhD and Andrew M. Evens, DO, MSc, FACP

In this episode, “Next Steps in HL”, Stephen M. Ansell, MD, PhD and Andrew M. Evens, DO discuss what’s coming. Current trials are integrating BV and checkpoint inhibitors into frontline, testing these agents for older patients, and defining effects in early-stage disease. A plethora of novel therapies are also being developed in relapsed/refractory disease. Implications of highly active agents on conventional standards of chemotherapy, radiation therapy, and transplantation options are discussed.

Share this story, choose your platform!